Introduction
OXA-48-type carbapenemases were first identified in 2001 in a carbapenem-resistant Klebsiella pneumoniae isolate from the urine of a patient hospitalized in Istanbul, Turkey. 1 Since then, reports of infections caused by OXA-48-producing Enterobacteriaceae have escalated-particularly in Europe, Asia and Africa, and less so in the Americas. [2] [3] [4] [5] There are six carbapenem-hydrolysing class D b-lactamase (CHDL) subgroups that are clinically significant: OXA-23, OXA-24/40, OXA-48, OXA-51, OXA-58 and OXA-143. 6 All except the OXA-48 group are predominantly found in Acinetobacter spp. isolates, 6 whereas OXA-48 enzymes are usually found in Enterobacteriaceae. 5 To date, 14 OXA-48-like variants have been described (OXA-48, -162, -163, -181, -199, -204, -232, -244, -245, -247, -370, -405, -436 and -484) of which 11 are CHDLs. These vary in sequence by one to five amino acids from the 'classical' OXA-48 variant and hydrolyse penicillins and carbapenems, but not extended-spectrum cephalosporins (e.g. cefepime and ceftazidime). 1 In contrast to their CHDL counterparts, OXA-163, -247 and -405 also differ from OXA-48 by one or two amino acids, but additionally have a four amino acid deletion in the active site region; as a result they lack significant carbapenemase activity, but do exhibit increased activity toward extended-spectrum cephalosporins. [7] [8] [9] bla OXA-48 has only been found in Enterobacteriaceae and has been associated with outbreaks in Turkey, the Middle East and North Africa. 5, 10 Other variants have different geographical associations: in particular bla OXA-181 and bla OXA-232 have been epidemiologically linked to the Indian subcontinent and are often co-harboured with NDM enzymes.
the Netherlands and France, suggesting the country-to-country transfer of this clone, 13 with patient-linked transfer of OXA-48-producing Enterobacter cloacae from Morocco to France also documented. 14 On the other hand, pOXA-48a, a 61.9 kb self-conjugative IncL/M plasmid, was shown to be the primary vehicle for dissemination of bla OXA-48 in several outbreaks. 5, 15 This broad host range plasmid harbours bla OXA-48 within Tn1999 and occurs across several enterobacterial species. 5, 15 This study describes the epidemiology of OXA-48-like carbapenemase producers submitted to PHE's Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit between 2007 and 2014.
Materials and methods

Bacterial isolates, identification and susceptibility testing
Isolates were submitted to PHE's AMRHAI Reference Unit from clinical laboratories across the UK between November 2007 and December 2014 for investigation of unusual resistance, including to carbapenems.
Bacterial identification was carried out using chromogenic agars [CHROMagar TM Orientation (CHROMagar, Paris, France) and Brilliance UTI (Oxoid, Basingstoke, UK)] together with API-20E tests (bioMérieux SA, Marcy-l' Etoile, France) or, since August 2012, by MALDI-TOF MS (Bruker Microflex LT; Bruker Daltonik GmbH, Bremen, Germany).
Antibiotic susceptibilities (MICs) were determined by BSAC agar dilution 16 using AMRHAI's standard Gram-negative antibiotic panel, which includes ertapenem, meropenem and imipenem (the latter with/without 320 mg/L EDTA to detect metallo-carbapenemases), and interpreted using EUCAST breakpoints. 17 
Screening for carbapenemase genes
Isolates displaying high-level resistance to piperacillin/tazobactam (MICs 64 mg/L) and temocillin (MICs 128 mg/L), as well as reduced susceptibility or resistance to any carbapenem, were tested for bla OXA-48-like genes by in-house PCR 1 and/or with a commercial microarray (Check-MDR CT102; Check-Points, Wageningen, The Netherlands). 18 In instances where imipenem potentiation by EDTA was observed, isolates were also tested by PCR for the presence of metallo-carbapenemases (bla NDM , bla VIM , bla IMP , bla GIM , bla SIM and bla SPM ) by in-house PCRs. 19 
WGS and analyses
Three hundred and seventy isolates, temporally and geographically distributed throughout the study, were selected for WGS. Genomes were sequenced using the Nextera sample preparation method with the standard 2% 100 base sequencing protocols on a HiSeq instrument (Illumina, San Diego, CA, USA). Data were analysed using an in-house bioinformatics pipeline as previously described. 20 STs were inferred from WGS data where MLST schemes exist.
For plasmid analysis, sequencing reads were mapped against known OXA-48 plasmids, namely pOXA-48a (NC_019154), pOXA-232 (JX423831), pKP3-A (NC_019160) and pOXA181 (KP400525).
Analysis of patient demographic information
Patient data were obtained from the request forms sent with submissions from referring laboratories. A patient was categorized as 'new' if they were found to have OXA-48-like-positive isolates detected by AMRHAI for the first time and 'known' if any OXA-48-like-positive isolate, irrespective of species, had previously been identified from the patient by AMRHAI.
Results
Demographics of affected patients and distribution
During the study period, AMRHAI confirmed 741 OXA-48-like positive isolates from 111 laboratories throughout the UK and obtained from 536 patients. Figure 1 illustrates the temporal distribution of these isolates among 'new' and 'known' patients, and among submitting laboratories. The first OXA-48-like positive isolate was a K. pneumoniae, submitted to AMRHAI in November 2007 and obtained from the urine of a patient previously hospitalized in Turkey. 10 Isolates with OXA-48-like carbapenemases were submitted from laboratories across all UK regions. The national distribution of affected patients was as follows: England (n " 514), Scotland (n " 13), Northern Ireland (n " 6) and Wales (n " 3). The greatest number of affected patients was in the London region (n " 203), followed by the North West (n " 143).
Most source patients were hospitalized (79%; 421 of 536), but a few were outpatients (7%; 38 of 536), in primary care (8%; 41 of 536) or in unknown settings (7%; 36 of 536). The mean patient age was 59.5 years and 54% (289 of 536) were male.
A travel history was reported for 130 of 536 (24%) patients. Of these, 55 patients had documented foreign travel to the following destinations: India (12), Turkey (9), Pakistan (5), Egypt (4), Libya (4), Spain (4), Kuwait (3), Malta (3), Sri Lanka (2), Tunisia (2) and single patients had travelled to Cyprus, Kenya, Morocco, Russia, Saudi Arabia, Singapore and Syria. Twenty patients were known to have been hospitalized while abroad in Egypt (4), Libya (4), Turkey (4), India (3), Pakistan (2), Cyprus (1), Spain (1) and Sri Lanka (1) .
Single OXA-48-like-positive isolates were referred from 408 of 536 (76%) patients and multiple isolates from the remaining 128 (24%). Among the patients with multiple OXA-48-like-positive isolates, 43 of 128 (34%) yielded isolates of different species or genera and 63 of 128 (49%) had isolates referred from different anatomical sites. The OXA-48-like-positive isolates were referred over a period of ,14 days in 65 of 128 (51%) instances, for 17 of 128 over a period of 14-28 days, 38 of 128 over a period of 1-6 months and over a period .6 months from 8 patients. Seventeen percent (127 of 741) of isolates were submitted from a single laboratory (laboratory 1), which serves three hospitals (to be subsequently known as hospitals A, B and C), over a 2 year period. Further details of the isolates from this laboratory are given below.
Microbiology
Most (99%; 736 of 741) submitted isolates were Enterobacteriaceae, comprising: K. pneumoniae (55%; 408 of 741), Escherichia coli (29%; 218 of 741), Enterobacter spp. (9%; 68 of 741), Klebsiella oxytoca (3%; 24 of 741), Citrobacter spp. (2%; 14 of 741), Serratia marcescens (.1%; 3 of 741) and one Raoutella ornithinolytica. There were also five non-Enterobacteriaceae isolates comprising Pseudomonas aeruginosa (n " 3; all from one patient) 21 and Shewanella spp. (n " 2; OXA-48-like enzymes are intrinsic in this genus).
If samples rather than patients were considered as the denominator, most were taken in hospitals (89%; 656 of 741), but some were general practice urines (6%; 45 of 741) and a few from unknown settings (5%; 40 of 741). The most frequently reported specimen type was urine (29%; 215 of 741), followed by faeces or Carbapenemase alleles and typing of the isolates WGS was undertaken for 351 non-duplicate isolates from single patients and their STs (where MLST schemes exist) and carbapenemase alleles were defined. These comprised: K. pneumoniae (n " 163), E. coli (n " 114), E. cloacae (n " 42), K. oxytoca (n " 13), Citrobacter spp. (n " 11), other Enterobacter spp. (n " 5), S. marcescens (n " 2) and P. aeruginosa (n " 1). Their carbapenemase genes comprised: bla OXA-48 (66%; 230 of 351), bla OXA-181 (18%; 62 of 351), bla OXA-232 (7%; 24 of 351), bla OXA-244 (3%; 10 of 351), bla OXA-245 (,1%; 1 of 351), bla OXA-484 (1%; 5 of 351), bla OXA-48 ! bla NDM-1 (1%; 5 of 351), bla OXA-181 ! bla NDM-1 (2%; 6 of 351) and bla OXA-232 ! bla NDM-1 (2%; 8 of 351). The carbapenemase variants and allele combinations OXA-48, OXA-181, OXA-48 ! NDM-1 and OXA-181 ! NDM-1 were found in multiple species. OXA-232, OXA-245, OXA-484 and OXA-232 ! NDM-1 were found only in K. pneumoniae isolates, while OXA-244 was found only in E. coli isolates. Numerous other genes encoding resistance to several other classes of antibiotics were also detected throughout all species (Table 2) . Overall, 19 of 351 (5%) isolates had OXA-48-like enzymes together with another carbapenemase, 266 of 351 (76%) also harboured a predicted ESBL or plasmid-encoded AmpC and 85 of 351 (24%) had OXA-48-like enzymes without any of these additional b-lactamase types.
K. pneumoniae
One hundred and sixty-three non-duplicate K. pneumoniae isolates, from 56 laboratories across 10 UK regions, were sequenced. Individual laboratories submitted between 1 and 15 isolates. Forty-nine STs were identified, the most frequent being ST14 (27 isolates from 17 centres over 16 months), followed by ST231 (18 from 14 centres over 15 months), ST147 (17 from 13 centres over 7 years), ST101 (13 from 10 centres over 4 years), ST11 (10 from 7 centres over 16 months) and ST16 (6 from 5 centres over 3 months). The remaining 43 STs were each represented by five isolates or fewer. Five OXA-48-like variants were identified [bla (n " 86), bla OXA-181 (n " 31), bla OXA-232 (n " 24), bla OXA-484 (n " 5) and bla OXA-245 (n " 1)] and 16 isolates produced more than one carbapenemase [bla 
Multiple plasmid replicon types were identified including IncL/M, IncA/C, several IncF variants, IncHI2, IncX3 and ColE-like replicons. Plasmid mapping revealed that 70 of 86 (81%) isolates with OXA-48 enzymes and 1 with OXA-245 had plasmids exhibiting .99% sequence identity to pOXA-48a, whereas among the 31 with OXA-181 enzymes 8 (26%) and 5 (16%) had plasmids with .99% sequence identity to pOXA181 and pKP3-A, respectively. All 32 isolates with OXA-232 enzymes had plasmids exhibiting .99% sequence identity to pOXA-232. pOXA-48a sequences were found in 37 STs, most frequently ST11 (n " 8) and ST101 (n " 9), whereas pOXA181 sequences were found in five STs (ST11, ST61, ST25, ST307 and ST709), each with one to three representatives; pKP3-A sequences were found in two STs, with one representative (ST395) and four representatives (ST147), respectively. pOXA-232 sequences were found in seven STs (ST14, ST15, ST16, Findlay et al.
ST147, ST231, ST307 and ST395), most often ST14 (15 isolates from 13 centres), ST231 (11 from 8 centres) and ST147 (3 from 2 centres). The earliest UK isolate with an OXA-48-like enzyme dated from 2007 and was from a patient who had previously been hospitalized in Turkey. 10 It was shown here to belong to ST147 and to harbour a pOXA-48a-like plasmid.
The most frequent submitter, laboratory 1, sent 15 isolates that were subjected to WGS over 22 months-13 of which were obtained from hospital A. These 15 represented 11 STs and all harboured plasmids with .99% sequence identity to pOXA-48a.
E. coli
One hundred and fourteen non-duplicate E. coli isolates, from 49 laboratories across seven UK regions, were sequenced. Laboratories submitted between 1 and 16 isolates and 37 STs were identified. The most frequent of these were ST38 (53 isolates from 34 laboratories over 42 months) and ST410 (12 from 9 laboratories over 20 months). The remaining 35 STs were each represented by four isolates or fewer. Three OXA-48-like variants were identified [bla (n " 74), bla OXA-181 (n " 30) and bla OXA-244 (n " 10)].
Multiple plasmid replicon types were identified including IncL/M, several IncF replicons, IncB/O, IncHI2, IncK and IncX3.
Plasmid analyses revealed that 22 of 74 (30%) E. coli with OXA-48 enzymes had plasmids exhibiting .99% sequence identity to pOXA-48a, and 22 of 30 (73%) of those with OXA-181 had plasmids that exhibited .99% sequence identity to pOXA181. pOXA48a sequences were found in 17 STs, each with one to four representatives. pOXA181 sequences were found in 10 STs, predominantly ST410 (n " 11), which were submitted from eight laboratories across five regions. No plasmid could be identified in 70 isolates. Of these, 50 belonged to ST38, 41 of them harbouring bla OXA-48 and 9 harbouring bla OXA-244 . The most frequent submitter, laboratory 1, sent 16 isolates that were subject to WGS over a 21 month period (14 of which were obtained from hospital A); these represented 14 STs, all had OXA-48 and 12 of 16 (75%) harboured pOXA-48a sequences.
Enterobacter spp.
Forty-seven non-duplicate Enterobacter spp. isolates, sent from 15 laboratories across seven UK regions, were sequenced. These comprised: E. cloacae (n " 42), Enterobacter aerogenes (n " 4) and Enterobacter hormaechei (n " 1). Individual laboratories submitted between 1 and 27 isolates. Forty-five isolates harboured bla OXA-48 and the remaining two isolates harboured bla OXA-48 ! bla NDM-1 . Thirteen STs were identified among the E. cloacae isolates, each with between 1 and 17 representatives. The most frequently OXA-48-like carbapenemases in the UK 
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Other species
The remaining 14 isolates that were sent for WGS comprised: Citrobacter freundii (n " 9), Citrobacter koseri (n " 2), S. marcescens (n " 2) and P. aeruginosa (n " 1). All harboured classical bla OXA-48 except for one C. freundii isolate, which harboured bla OXA-181 ! bla NDM-1 , and the P. aeruginosa isolate that had bla OXA-181 . The P. aeruginosa isolate was previously found to belong to ST773 with bla OXA-181 encoded within Tn2013. 21 Plasmid replicon types included IncL/M, several IncF replicons and IncA/C. Within the nine C. freundii isolates eight STs were identified. Five of these were obtained from inpatients in hospital A, three of which harboured pOXA-48a sequences. In the remaining isolates, two C. koseri isolates that produced OXA-48 shared .99% identity to plasmid pOXA-48a and one OXA-181-producing C. freundii isolate shared .99% identity to pKP3-A.
Antibiotic susceptibility
MIC distributions for OXA-48-like-positive isolates are shown in Table 3 . Ninety-nine percent (724 of 728) of isolates with available susceptibility data were resistant or non-susceptible to ertapenem; however, 42% (312 of 735) and 54% (400 of 735) remained susceptible to imipenem and meropenem, respectively, based on EUCAST breakpoints. In all but eight cases, MICs of meropenem were above the EUCAST screening cut-off concentration of 0.125 mg/L. 22 For the remaining eight cases the imipenem MICs were also below the EUCAST screening cut-off of 1 mg/L, but were above the ertapenem MIC cut-off of 0.125 mg/L. All eight isolates were E. coli and the analysis of seven of these by WGS indicated that six different STs and two OXA-48-like variants [bla OXA-48 (five) and bla OXA181 (two)] were represented. Piperacillin/tazobactam resistance (MIC .16 mg/L) was observed in 732 of 734 of tested isolates (data not shown). All the isolates that co-produced either NDM or VIM enzymes were non-susceptible to all three carbapenems. Non-susceptibility to ceftazidime and cefotaxime was observed in 69% and 89% of isolates. Non-susceptibility to the aminoglycosides amikacin, gentamicin and tobramycin was observed in 26%, 55% and 61% of isolates, respectively. Almost all (28 of 34) isolates that co-produced another carbapenemase were non-susceptible to all three aminoglycosides and all were resistant to ciprofloxacin. Most (91%; 659 of 722) isolates were susceptible to colistin.
Colistin resistance was observed in 63 isolates, submitted from 32 laboratories over 6 years, the majority (54 of 63) of which were K. pneumoniae and had MICs in the range of 4 to .32 mg/L. Sequencing of 22 of 54 colistin-resistant K. pneumoniae isolates identified 10 STs, 6 of which were represented by a single isolate and the 4 remaining STs were as follows: ST14 (6), ST101 (4), ST147 (2) and ST231 (4). These 22 were submitted from 14 laboratories across five regions. For 10 isolates colistin MICs were .32 mg/L; these comprised 7 K. pneumoniae and 1 E. coli along with 2 S. marcescens with inherent resistance. These were referred from 10 laboratories across four regions. Non-susceptibility to ciprofloxacin and tigecycline was observed in 63% and 32% of isolates, respectively.
Discussion
This report reviews all isolates producing an OXA-48-like carbapenemase and referred to PHE's AMRHAI Reference Unit from laboratories across the UK between November 2007 and December 2014. Over this study period, 741 OXA-48-like-positive isolates were obtained from 536 patients across all UK regions.
The majority of isolates were from clinical specimens, predominantly urines. All isolates were resistant to at least two classes of antibiotics and most were non-susceptible at EUCAST breakpoints to at least one of the three carbapenems tested. A high rate of susceptibility was maintained only to colistin (91%), with amikacin (74%) and tigecycline (68%) next in rank order. High levels of resistance to the third-generation cephalosporins, ceftazidime and cefotaxime, could be attributed to the co-carriage of ESBL/AmpC enzymes in 76% of sequenced isolates. There was huge variation in susceptibility to other antibiotics tested in this study, attributable to the presence of a plethora of other resistance genes, as identified in the WGS analyses (Table 2 ), sometimes including other carbapenemase genes-5% (34 of 741) of isolates with OXA-48-like enzymes also harbouring either a bla NDM (33 of 741) or bla VIM (1 of 741) allele. It follows that there can be no 'standard' antibiotic regimen for the treatment of infections caused by OXA-48-like producers without additional susceptibility testing and/or resistance gene data, although ceftazidime/avibactam shows promise based on in vitro data. 23 Although colistin, tigecycline and amikacin retained the highest levels of susceptibility their individual indications may make them unsuitable for the treatment of some infections. For example, tigecycline cannot be used for the treatment of urinary tract infections 24 and colistin use has been associated with both neurotoxicity and nephrotoxicity. 25 OXA-48-like carbapenemases in the UK JAC Table 3 . MIC distributions for OXA-48-like-positive isolates (n " other spp. 
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At the time of writing, there are 14 known OXA-48-like variants, 11 of them CHDLs, and WGS analysis of 351 non-duplicate UK isolates identified 5 of the CHDL types. OXA-48 was by far the most common variant, found in two-thirds (235 of 351) of isolates. The earliest OXA-48-positive isolate identified in the UK was obtained in 2007 from a patient who had recently been hospitalized in Turkey; this isolate was shown here to be an ST147 K. pneumoniae carrying a plasmid with .99% identity to pOXA-48a. pOXA-48a has been implicated in early OXA-48 dissemination in Turkey. 15, 26 A travel history was available for only 24% of patients, of whom 42% had documented travel to 17 different countries, several of which have previously reported outbreaks involving bacteria with OXA-48-like enzymes. 2, 4, 5, 27 All five patients with reported travel to Turkey and six of seven with travel to other Middle Eastern or North African countries whose isolates were analysed by WGS were found to carry organisms with bla OXA-48 , as repeatedly found in Turkey. 26, 27 By contrast, both OXA-181 and OXA-232 have been associated with the Indian subcontinent, 12, 28 and were found in 12 of 13 sequenced isolates from patients reporting travel to India, Pakistan or Sri Lanka. These data further underscore the role that international travel may play in carbapenemase dissemination. Notably four K. pneumoniae with OXA-48-like enzymes were from patients transferred to the UK for intensive care treatment of injuries received during the Libyan 'Emergency' of 2011.
Forty-four percent (154 of 351) of sequenced isolates and 153 of 235 of those with classical bla OXA-48 possessed DNA with .99% sequence identity to pOXA-48a, an IncL/M plasmid of 62 kb first associated with bla OXA-48 , in Turkey and North Africa and now with multiple polyclonal and cross-species outbreaks. 15 pOXA-48a-like sequences were found here in multiple species and STs. Except for one isolate with bla OXA-245 these all carried bla OXA-48 . The demonstration of both the broad range and success of this plasmid supports an earlier and much smaller analysis where we found IncL/M OXA-48 plasmids among several enterobacterial species and STs. 10 Of the remaining 197 isolates sequenced, 68 carried DNA with .99% identity to one of three plasmids: pOXA-232 (32 of 68), pOXA181 (30 of 68) or pKP3-A (6 of 68). pOXA-232 and pKP3-A are ColE-like plasmids, of 6 and 7.6 kb, respectively, originally discovered in E. coli and K. pneumoniae isolates obtained from patients following hospitalization in India. 28, 29 All of the 32 sequenced isolates harbouring bla OXA-232 and 6 of 69 isolates with bla OXA-181 contained sequences with .99% sequence identity to pOXA-232 and pKP3-A, respectively. Thirty further isolates with OXA-181 enzymes were shown to carry DNA with .99% sequence identity to pOXA181, an IncX3 plasmid of 51.5 kb that was first found in an E. coli ST410 isolate obtained from the blood sample of a patient in China who had no history of travel to the Indian subcontinent. 30 We found bla OXA-48-like genes in multiple species and STs and that some clones were particularly successful as a vehicle for bla OXA-48-like dissemination. In K. pneumoniae some STs (such as ST14 and ST147) were associated with multiple OXA-48-like plasmids, indicating the success of the ST, but not indicating expansion of a specific clone/plasmid pairing. Although K. pneumoniae ST395 has been associated with outbreaks in Europe and Morocco, 13 we found only two representatives among those sequenced and these harboured different OXA-48-like variants, bla OXA-48 and bla OXA-181 , in different genetic environments; one in a pKP3-A sequence and the other in an unidentified environment. 
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Rather alarmingly, 16% of isolates were submitted from a single hospital, hospital A, representing at least six species and 33 STs. Within the 61 isolates from hospital A that were sequenced, most (54 of 61) harboured pOXA-48a sequences. This suggests the local spread of pOXA-48a among different genera, species and STs within this hospital and is indicative of the success of pOXA-48a in dissemination.
In contrast to the ST diversity among K. pneumoniae isolates with OXA-48-like enzymes ST38 accounted for almost half of all the sequenced E. coli isolates with OXA-48-like enzymes (53 of 114). ST38 has previously been associated with bla CTX-M carriage in multiple countries. 31 Plasmid mapping could not establish a location for bla in most (50 of 53) of these isolates. In a previous study 10 the authors failed to obtain any plasmid transformants from ST38 isolates and, more recently, it was reported that bla OXA-48 and bla OXA-244 can be chromosomally encoded in ST38 isolates. 32 This may apply here, but establishing this would require utilization of longer read sequencing techniques (e.g. PacBio and MinION).
In conclusion, this study has shown an increase in OXA-48-like enzymes in the UK over a 7 year period. We suggest that the accumulation of OXA-48-like carbapenemases within the UK is due to repeated import, coupled with both the dissemination of successful plasmids, notably pOXA-48a, and the spread of successful clones (e.g. E. coli ST38); the linkage to plasmid spread was particularly strong.
